öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£ºÁõæ¿èå
ÐÔ±ð£ºÅ®
ÈËÆøÖ¸Êý£º166

ËùÊôԺУ£º¹ãÎ÷Ò½¿Æ´óѧ
ËùÊôԺϵ£ºÖ×ÁöҽѧԺ
Ö°³Æ£º¸±½ÌÊÚ
µ¼Ê¦ÀàÐÍ£ºË¶µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º¸¾²ú¿Æѧ
Ñо¿ÁìÓò£º ¸¾¿Æ¶ñÐÔÖ×ÁöÁÙ´²¼°»ù´¡Ñо¿
Ñо¿ÁìÓò£º ¸¾¿Æ¶ñÐÔÖ×ÁöÁÙ´²¼°»ù´¡Ñо¿ [ÊÕÆð]




¸öÈ˼òÊö :
2010Äê±ÏÒµÓÚ±±¾©´óѧ£¬»ñ¸¾²ú¿Æѧ²©Ê¿Ñ§Î»£¬2012ÄêÓÚÇ廪´óѧ½øÐÐ2Ä격ʿºóÑо¿¹¤×÷²¢ÒÔ´ð±çÓÅÐã³öÕ¾¡£²©Ê¿ºó³öÕ¾ºóÓÚ¹ãÎ÷Ò½¿Æ´óѧÖ×ÁöҽѧԺ´Óʸ¾¿ÆÖ×Áö½Ìѧ¡¢¿ÆÑм°ÁÙ´²¹¤×÷²¢½Ï»ýÀ۷ḻ¾­Ñé¡£????ÔÚ½Ìѧ·½Ã棬»ý¼«²ÎÓëÁÙ´²ÐÍÑо¿ÉúµÄ´ø½Ì¹¤×÷£¬²ÎÓëÖ¸µ¼¶àÃû¿ÆѧÐÍÑо¿Éú¿ÎÌâÉè¼Æ¡¢¿ªÌⱨ¸æ¡¢ÊµÑéÑо¿¼°ÂÛÎÄ׫д£¬µÃµ½´ø½ÌÑо¿ÉúµÄÒ»ÖºÃÆÀ¡£¹²´ø½Ì¶àÃûÁÙ´²ÐÍÂÖתÑо¿ÉúÁÙ´²¼ûÏ°Ñо¿Éú£¬Ö¸µ¼ÁÙ´²Ñо¿Éú½øÐÐÁÙ´²Ñо¿²¢×«Ð´SCIÂÛÎÄ¡£´ËÍâÓÚ2014Äê5Ô·ݲμÓÁ˱¾¿ÆÉúÁÙ´²¼¼ÄܲÙ×÷¿Î³Ì´ø½ÌÈÎÎñ£¬´ø½Ì¹ý³ÌÒàÊܵ½Ñ§ÉúµÄ»¶Ó­¼°ºÃÆÀ¡£????

¿ÆÑй¤×÷ :
¿ÆÑй¤×÷ÉÏ£¬¾­¹ý¶àÄê¿ÆÑо­Àú£¬¾ßÓзḻ¼°È«ÃæµÄ¿ÆÑо­Ñé¡£¼á³Ö·¢»ÓöλÔÓéÀֵǼÈë¿ÚÏÂÔØÌس¤£¬¹Ø×¢±¾ÁìÓòÑо¿¶¯Ïò£¬ÖÂÁ¦ÓÚ¸¾¿Æ¶ñÐÔÖ×ÁöÁÙ´²¼°»ù´¡Ñо¿£¬2013ÄêÉ걨¿ÎÌâ¡°HPV16?¸ÐȾ¶ÔÓÚËÞÖ÷¹¬¾±ÉÏƤϸ°ûmicroRNA?µÄÓ°Ïì¼°Æä×÷ÓûúÖÆ¡±»ñµÃ¹ãÎ÷×ÔÈ»¿Æѧ»ù½ð×ÊÖú£¨ÏîÄ¿±àºÅ£º2013GXNSFBA019195£©£¬¾­·Ñ5Íò£»2015ÄêÉ걨¿ÎÌâ¡°¸ßΣÐÍHPVÖ°©Òò×ÓE5ÔÚ¹¬¾±°©ÖеÄ×÷Óü°Æä»úÖÆ¡±»ñµÃ¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð×ÊÖú£¨ÏîÄ¿Åú×¼ºÅ£º**£©£¬¾­·Ñ37Íò¡£½ü5Äê·¢±íSCIÂÛÖø£º1.?Liu?CZ,?Zeng?HX,?Zhao?JJ,?Rong?Y,?Mo?ZL,?Li?LA,?et?al.?The?Validity?of?Using?Human?Squamous?Cell?Carcinoma?Associated?Antigen?and?Cytokeratin?19?Fragment?Antigen?21-1?to?Predict?Postoperative?Adjuvant?Radiotherapy?for?Nonbulky?Early-Stage?Squamous?Cell?Carcinoma?of?the?Cervix.?Int?J?Gynecol?Cancer?2017,27:994-1000.(IF:2.369)2.?C.?Liu,?J.?Lin,?L.?Li,?Y.?Zhang,?W.?Chen,?Z.?Cao,?H.?Zuo,?C.?Chen,?and?K.?Kee,?Hpv16?Early?Gene?E5?Specifically?Reduces?Mirna-196a?in?Cervical?Cancer?Cell,?Sci?Rep,?5?(2015),?7653.£¨IF£º5.578£©3.?Liu?CZ,?Zhang?L,?Chang?XH,?Cheng?YX,?Cheng?HY,?Ye?X,?Fu?TY,?Chen?J,?Cui?H.,Overexpression?and?immunosuppressive?functions?of?transforming?growth?factor?1,?vascular?endothelial?growth?factor?and?interleukin-10?in?epithelial?ovarian?cancer.Chin?J?Cancer?Res.?2012?Jun24(2):130-7.?(IF:2.116)¡£